Abstract:Background PRJ1–3024 is a small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor designed to enhance T-cell function and anti-tumor responses. HPK1 is an immunosuppressive regulatory kinase with a restricted expression profile in hematopoietic compartment.1 2 HPK1 kinase activity suppresses immune functions of a wide range of cells including cluster of differentiation CD4+ T cells, cluster of differentiation CD8+ T cells, and dendritic cells (DCs). Inactivating kinase domain of HPK1 is sufficient to elicit anti-tumor immune responses.3 It was demonstrated that HPK1 mediates T-cell dysfunction and is a potential therapeutic target for T-cell-based immunotherapies.4 These results strongly support a small molecule inhibitor of HPK1 functioning as a cancer immunotherapy agent. Methods Phase 1, multicenter, non-randomized, open-label study to evaluate the safety, tolerability, and preliminary efficacy in patients with advanced solid tumors. The primary objective is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The secondary objectives are to evaluate safety, PK, pharmacodynamics of PRJ1–3024, and evaluate preliminary efficacy of PRJ1–3024. PRJ1–3024 is administered orally once daily (QD). Each cycle is 21 days with dose-limiting toxicity (DLT) assessment to be completed after 21 days on treatment in Cycle 1. Changes in multiple cytokines and chemokines in plasma and effects on phosphor-SLP-76 and proinflammatory cytokines in activated PBMCs will be evaluated. Pre- and Post-dose tumor tissue samples will be used for isolation of tumor-infiltrating lymphocytes to investigate the effects on the activation, expansion and migration of immune cells. Results As of June 01, 2023, 16 patients with advanced solid tumors were enrolled in 5 dose cohorts: 80, 160, 300, 500, and 600mg. Median age was 64.7 years (range 42–84). Diagnoses were NSCLC(3 pts), Small Cell Lung Carcinoma (3 pts), Urothelial Carcinoma (3 pts), Gastroesophageal Junction (1), Cutaneous Melanoma (1), Cutaneous Squamous Carcinoma (1), HCC (1), HNSCC (1), TNBC (1), and Prostate Cancer (1). Eleven patients (69%) had ≥ 4 prior cancer therapies, 14 patients had prior treatment with immune checkpoint inhibitors. The most common TEAEs (in >2 patients) were diarrhea (7 pts), nausea (6 pts), blood creatinine increased (3 pts), fatigue (3 pts), and vomiting (3 pts). PK and PD assessments will be updated at time of presentation. Conclusions PRJ1–3024 is a potent inhibitor of HPK1 that is shown to be well tolerated. Further safety and efficacy results will be presented at the meeting including additional cohorts if available. Trial Registration Clinicaltrials.gov: NCT05315167 References Shui JW, Boomer JS, Han J, et al. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses. Nat Immunol. 2007;8(1):84–91. Wang X, Li JP, Chiu LL, et al. Attenuation of T cell receptor signaling by serine phosphorylation-mediated lysine 30 ubiquitination of SLP-76 protein. J Biol Chem. 2012;287(41):34091–34100. Hernandez S, Qing J, Thibodeau RH, et al. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. Cell Rep. 2018;25(1):80–94 Si J, Shi X, Sun S, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020;38(4):551–566.e11. Ethics Approval Advarra IRB Approval: MOD01175260 Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. All participants gave informed consent before taking part in this clinical trial.

Abstract 7177: Development and validation of clinical pharmacodynamic biomarkers to assess treatment response to HPK1 inhibition and guide dosing decisions

Abstract 2653: Integrative analysis of proteomic alterations in human PBMC's treated by HPK1 inhibitor FB849 reveals enriched pathways from various immune cells leading to potential novel biomarker discovery

Abstract 2097: ABT co-dose accelerated target validation with a fit-for-purpose HPK1 inhibitor tool

1073 A Phase 1, First-in-human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PRJ1–3024in Subjects with Advanced Solid Tumors

Abstract 3967: ISM9182A, a novel HPK1 inhibitor, exhibits immune modulatory activity and robust monotherapy anti-tumor effects in preclinical studies

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

Abstract 6485: Profile guided low dose drug combination strategies and kinase activities with prognostic and therapeutic avenues in pancreatic ductal adenocarcinoma

Abstract 6510: BPI-511966,a potent and selective HPK1 inhibitor with robust single-agent efficacy for cancer immunotherapy

Abstract PO4-05-05: Immune Activation Signatures for predicting CDKi primary response in advanced breast cancer patients

Abstract 4514: Discovery of potent and orally bioavailable degraders of HPK1 based on a novel HPK1 binder

Abstract 5147: Identification of pharmacodynamic biomarkers in PBMCs and cancer cells for SIK2 kinase inhibitor therapy

Abstract 3631: Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications

Abstract 4029: HPK1 inhibitor reinvigorates exhausted tumor-infiltrating CD8 T cells and synergizes with anti-PD-1 blockade in gynecologic malignancies

Abstract 2651: A selective HPK1 inhibitor FB849 reprograms intratumoral immune cells and elicits strong anti-cancer immunity

Abstract 3548: Role of the cancer cell proteome and tumor microenvironment in the hyperprogression (HP) phenotype response to immune checkpoint blockade

Abstract 2461: Discovery of an orally available and liver-targeted ALPK1 agonist for cancer immunotherapy

Abstract 2771: Circulating biomarkers to predict antitumor response to immunotherapy in advanced unresectable hepatoma

Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues As Novel HPK1 Inhibitors

Abstract 6253: Single-cell RNA sequencing reveals metastatic site-specific biomarkers for predicting response to CDK4/6 inhibition in advanced HR+/HER2- breast cancer

Abstract 2652: NDI-101150 is a potent and highly selective HPK1 inhibitor that both synergizes with and differentiates from anti-PD1 immune checkpoint blockade

Abstract 2654: HPK1 inhibits CD8+ T cell effector gene expression following T cell activation